NASDAQ
RDHL

Redhill Biopharma Ltd

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Redhill Biopharma Ltd Stock Price

Vitals

Today's Low:
$0.82
Today's High:
$0.8598
Open Price:
$0.8598
52W Low:
$0.795
52W High:
$38.4
Prev. Close:
$0.84
Volume:
46710

Company Statistics

Market Cap.:
$4.91 million
Book Value:
1.086
Revenue TTM:
$35.75 million
Operating Margin TTM:
-78.01%
Gross Profit TTM:
$45.25 million
Profit Margin:
32.37%
Return on Assets TTM:
-17.17%
Return on Equity TTM:
-884.29%

Company Profile

Redhill Biopharma Ltd had its IPO on 2013-01-07 under the ticker symbol RDHL.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Redhill Biopharma Ltd has a staff strength of 113 employees.

Stock update

Shares of Redhill Biopharma Ltd opened at $0.86 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.82 - $0.86, and closed at $0.86.

This is a +1.79% increase from the previous day's closing price.

A total volume of 46,710 shares were traded at the close of the day’s session.

In the last one week, shares of Redhill Biopharma Ltd have slipped by -2.73%.

Redhill Biopharma Ltd's Key Ratios

Redhill Biopharma Ltd has a market cap of $4.91 million, indicating a price to book ratio of 4.6005 and a price to sales ratio of 0.2159.

In the last 12-months Redhill Biopharma Ltd’s revenue was $35.75 million with a gross profit of $45.25 million and an EBITDA of $-24068000. The EBITDA ratio measures Redhill Biopharma Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Redhill Biopharma Ltd’s operating margin was -78.01% while its return on assets stood at -17.17% with a return of equity of -884.29%.

In Q2, Redhill Biopharma Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a negative 90.2%.

Redhill Biopharma Ltd’s PE and PEG Ratio

Forward PE
1428.5714
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-7.81 per share while it has a forward price to earnings multiple of 1428.5714 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Redhill Biopharma Ltd’s profitability.

Redhill Biopharma Ltd stock is trading at a EV to sales ratio of 1.7286 and a EV to EBITDA ratio of -3.9033. Its price to sales ratio in the trailing 12-months stood at 0.2159.

Redhill Biopharma Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$35.04 million
Total Liabilities
$28.19 million
Operating Cash Flow
$0
Capital Expenditure
$7000
Dividend Payout Ratio
0%

Redhill Biopharma Ltd ended 2024 with $35.04 million in total assets and $0 in total liabilities. Its intangible assets were valued at $35.04 million while shareholder equity stood at $3.47 million.

Redhill Biopharma Ltd ended 2024 with $0 in deferred long-term liabilities, $28.19 million in other current liabilities, 4620000.00 in common stock, $-382009000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.00 million and cash and short-term investments were $7.01 million. The company’s total short-term debt was $1,290,000 while long-term debt stood at $0.

Redhill Biopharma Ltd’s total current assets stands at $27.05 million while long-term investments were $0 and short-term investments were $18000.00. Its net receivables were $5.95 million compared to accounts payable of $3.11 million and inventory worth $4.94 million.

In 2024, Redhill Biopharma Ltd's operating cash flow was $0 while its capital expenditure stood at $7000.

Comparatively, Redhill Biopharma Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.86
52-Week High
$38.4
52-Week Low
$0.795
Analyst Target Price
$40

Redhill Biopharma Ltd stock is currently trading at $0.86 per share. It touched a 52-week high of $38.4 and a 52-week low of $38.4. Analysts tracking the stock have a 12-month average target price of $40.

Its 50-day moving average was $1.13 and 200-day moving average was $4.54 The short ratio stood at 0.02 indicating a short percent outstanding of 0%.

Around 437% of the company’s stock are held by insiders while 1111.4% are held by institutions.

Frequently Asked Questions About Redhill Biopharma Ltd

The stock symbol (also called stock or share ticker) of Redhill Biopharma Ltd is RDHL

The IPO of Redhill Biopharma Ltd took place on 2013-01-07

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
$68.32
-0.88
-1.27%
$227.35
-19.95
-8.07%
$165.9
-7.4
-4.27%
$1715
-80.5
-4.48%
$4.95
-0.25
-4.81%
ATLANTA LTD. (ATLANTA)
$13.85
-0.25
-1.77%
$3087.75
-64.4
-2.04%
$8.71
0.04
+0.46%
$16.32
0.01
+0.06%
$166.03
2.24
+1.37%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn’s disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Address

21 Ha?arba?a Street, Tel Aviv, Israel, 6473921